Maximus (NYSE:MMS) Lowered to "Hold" Rating by Wall Street Zen

Key Points

• Wall Street Zen downgraded Maximus to “Hold” from “Buy”, following similar rating reductions by Zacks Research and Weiss Ratings; MarketBeat data shows the stock has an overall “Hold” consensus.
• Maximus narrowly beat quarterly EPS expectations at $2.22, but revenue fell 5.1% year over year to $1.28 billion, below the $1.33 billion consensus estimate.
• The company’s fiscal 2026 EPS guidance is $7.90–$8.20, below the $8.43 analyst consensus, creating a key overhang despite profitability and margin strength; institutional investors own 97.21% of shares.

Maximus (NYSE:MMS - Get Free Report) was downgraded by research analysts at Wall Street Zen from a "buy" rating to a "hold" rating in a research report issued to clients and investors on Saturday.

MMS has been the subject of a number of other reports. Zacks Research lowered shares of Maximus from a "strong-buy" rating to a "hold" rating in a report on Monday, April 27th. Weiss Ratings cut Maximus from a "hold (c)" rating to a "hold (c-)" rating in a research report on Wednesday, May 20th. Two investment analysts have rated the stock with a Hold rating, According to data from MarketBeat, Maximus has an average rating of "Hold".

Maximus Stock Performance

Shares of MMS stock opened at $59.21 on Friday. The company has a market capitalization of $3.11 billion, a price-to-earnings ratio of 8.75 and a beta of 0.59. The company has a debt-to-equity ratio of 0.90, a quick ratio of 2.21 and a current ratio of 2.42. Maximus has a one year low of $52.73 and a one year high of $100.00. The company's 50-day moving average is $58.63 and its 200 day moving average is $67.46.

Maximus (NYSE:MMS - Get Free Report) last issued its earnings results on Thursday, August 6th. The health services provider reported $2.22 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.21 by $0.01. The business had revenue of $1.28 billion during the quarter, compared to analysts' expectations of $1.33 billion. Maximus had a net margin of 7.07% and a return on equity of 24.91%. The business's revenue for the quarter was down 5.1% compared to the same quarter last year. During the same period in the previous year, the company earned $2.16 earnings per share. Maximus has set its FY 2026 guidance at 7.900-8.200 EPS. Sell-side analysts expect that Maximus will post 8.05 EPS for the current fiscal year.

Institutional Trading of Maximus

A number of institutional investors have recently made changes to their positions in MMS. Farther Finance Advisors LLC raised its holdings in shares of Maximus by 69.0% during the fourth quarter. Farther Finance Advisors LLC now owns 284 shares of the health services provider's stock valued at $25,000 after purchasing an additional 116 shares during the last quarter. Advisory Services Network LLC purchased a new stake in Maximus in the third quarter worth approximately $32,000. Canada Pension Plan Investment Board bought a new stake in Maximus in the 2nd quarter worth approximately $35,000. Northwestern Mutual Wealth Management Co. grew its position in Maximus by 225.2% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 439 shares of the health services provider's stock worth $38,000 after purchasing an additional 304 shares during the period. Finally, Richardson Financial Services Inc. raised its stake in Maximus by 29.6% during the 4th quarter. Richardson Financial Services Inc. now owns 451 shares of the health services provider's stock valued at $39,000 after buying an additional 103 shares during the last quarter. Hedge funds and other institutional investors own 97.21% of the company's stock.

Key Stories Impacting Maximus

Here are the key news stories impacting Maximus this week:

• Positive Sentiment: Fiscal Q3 adjusted earnings were $2.22 per share, ahead of analyst estimates of approximately $2.20–$2.21 and up from $2.16 a year earlier. Higher margins also supported the quarter’s bottom-line performance. Maximus Q3 Earnings Beat Estimates, Increase Year Over Year
• Positive Sentiment: The earnings beat, year-over-year EPS growth and stronger margins indicate that Maximus is maintaining profitability even as sales soften. Maximus Q3 Earnings Beat Estimates
• Neutral Sentiment: Management’s fiscal Q3 earnings call focused on the quarterly performance and updated outlook, providing investors with additional context on operating trends and the company’s expectations for the remainder of fiscal 2026. Maximus Q3 2026 Earnings Call Transcript
• Negative Sentiment: Revenue was $1.28 billion, below the $1.33 billion consensus estimate and down 5.1% year over year. The shortfall suggests softer demand or project timing is limiting growth. Maximus Fiscal Q3 Earnings Snapshot
• Negative Sentiment: Maximus reduced fiscal 2026 EPS guidance to $7.90–$8.20, below the consensus estimate of $8.43. Revenue guidance of $5.2–$5.4 billion remains broadly in line with expectations at the midpoint, but the lower profit outlook is a key overhang for MMS. Updated Maximus Fiscal 2026 Guidance

Maximus Company Profile

Maximus, Inc NYSE: MMS is a global provider of government services focused on delivering health and human services programs. The company partners with federal, state, and local agencies to administer and manage programs that support individuals and families across various stages of life. Key service areas include eligibility determination and enrollment services for Medicaid, Medicare, Children's Health Insurance Program (CHIP) and other public assistance programs, as well as call center operations, case management and program integrity solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source